A practical way to think about it is in three buckets: Short-term refractive changes (often related to glucose shifts, hydration, or fatigue) Medication-associated systemic effects (hypotension, dehydration, electrolyte imbalance) True ocular pathology (retinopathy progression, optic nerve issues, retinal detachment, acute glaucoma) While Zepbound does not directly damage the eyes in most people, it can create conditions where vision changes occur
doi: 10.1210/jcem-71-5-1356 13 PaltaMLeCaireTJSadek-BadawiMHerreraVMDanielsonKK
Individually, each compound is a powerhouse
The GLP-1 pathway primarily controls appetite and incretin response, while the SGLT2 pathway directly removes excess glucose through urinary excretion
It is a healthcare, social media, psychological and regulatory issue all at once
This is especially true for new drugs like tirzepatide, where the full risks are not yet fully understood